enGene Holdings (ENGN) AI Stock Analysis

• Market Cap: $485.67M
• Dividend Yield: N/A
• Average Volume (3M): 457.18K
• Price to Earnings (P/E): 5.4
• Beta (1Y): 0.65
• Revenue Growth: N/A
• EPS Growth: -52.86%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 66,989,460
• 10 Day Avg. Volume: 908,583
• 30 Day Avg. Volume: 457,178
• PEG Ratio: 0.06
• Price to Book (P/B): 2.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.66
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -575.66
• Enterprise Value/Ebitda: -2.83
• 1Y Price Target: $25.67
• Price Target Upside: 254.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -2.07
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $7.00 ▼(-3.45% Downside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is held down primarily by weak financial performance (no revenue, inconsistent profitability, and substantial ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD and very low RSI/stochastics). A low P/E and a relatively strong balance sheet provide partial support but do not offset the operating and cash-flow risks.

Positive Factors

Proprietary delivery platform

A proprietary non-viral delivery platform is a durable competitive asset: it differentiates the company in gene delivery, supports localized administration (reducing systemic toxicity), and can enable multiple indications or licensing deals. This structural tech advantage can underpin sustained R&D value and partnership potential over the next several quarters.

Balance sheet strength and low leverage

A sizable equity base and minimal debt provide meaningful runway and financial flexibility for a clinical-stage biotech. This reduces immediate insolvency and interest-pressure risks, allows continued investment in clinical programs without urgent default risk, and supports strategic options like partnerships or staged financings over the medium term.

Clinical-stage pipeline focused on bladder cancer

A clear clinical focus with a lead bladder cancer program affords defined milestone timelines and regulatory pathways. Localized bladder delivery aligns with the company’s platform strengths, improving the odds of clinically meaningful readouts and creating discrete value inflection points that can drive durable partnership or licensing interest if trials show efficacy.

Negative Factors

Pre-revenue with negative gross profit

Being effectively pre-revenue with persistent negative gross profit means the company cannot internally fund development from commercial cash flow. That structural business weakness forces reliance on external capital or partners, elevating execution and dilution risk and making long-term financing and program continuity contingent on successful clinical progress.

Worsening operating cash burn

Rapidly increasing negative operating cash flow materially shortens runway absent new funding. Even with a solid equity balance, sustained high burn rates force frequent financing, increase dilution risk, and constrain strategic options. Management attention and resources may shift from execution to capital raises, which slows long-term program advancement.

Volatile, non-durable profitability

Sharp swings in reported earnings driven by non-operating items indicate earnings are not reflective of a stable operating business. This volatility undermines predictability for investors and partners, hampers internal planning, and signals that underlying operations have not yet achieved the consistency needed to self-sustain R&D or scale commercial activities.

enGene Holdings Business Overview & Revenue Model

Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

How the Company Makes Money

null

enGene Holdings Financial Statement Overview

Summary

Overall fundamentals are weak for a development-stage biotech: no revenue, consistently negative gross profit, volatile net results, and heavy ongoing operating/free-cash-flow burn (TTM OCF -$102.4M; TTM FCF -$103.8M). The main offset is a comparatively solid balance sheet with sizable equity and low debt, which provides some runway but does not resolve earnings quality concerns.

Income Statement

ENGN is still effectively pre-revenue (total revenue is 0 across periods), so profitability is being driven by non-operating items rather than a commercial business. Results are volatile: net income swung from a large loss in 2023 (-$99.9M) to a large profit in 2025 (+$117.3M), then back to a loss in TTM (Trailing-Twelve-Months) (-$11.3M). Gross profit is consistently negative, and operating performance is inconsistent (EBIT ranges from -$123.2M in 2025 to +$48.8M in TTM), highlighting weak underlying earnings quality at this stage.

Balance Sheet

The balance sheet is a relative strength. Equity is sizable and improved to $281.5M in TTM (Trailing-Twelve-Months) versus $72.5M in 2023, supporting the asset base ($337.1M TTM). Leverage appears manageable: total debt is $8.5M in TTM and debt-to-equity is low (~0.19). Key risk is returns: profitability is not durable, with return on equity negative in TTM and several years, reflecting ongoing losses and the early-stage nature of the business.

Cash Flow

Cash generation is weak, with persistent cash burn. Operating cash flow is deeply negative and worsening: -$24.7M (2023) to -$99.2M (2025) and -$102.4M in TTM (Trailing-Twelve-Months). Free cash flow is also consistently negative (TTM: -$103.8M). While free cash flow growth shows a rebound in TTM (improvement versus 2025), the company still relies on external funding to sustain operations until revenues materialize.

Breakdown	TTM	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-596.00K	-509.00K	-323.00K	-175.00K	0.00	0.00
EBITDA	-121.05M	-113.80M	-52.04M	-94.77M	268.73K	47.00K
Net Income	-11.30M	117.30M	-55.14M	-99.92M	30.73K	-23.44M
Balance Sheet
Total Assets	337.11M	221.47M	311.17M	86.96M	132.04M	131.45M
Cash, Cash Equivalents and Short-Term Investments	275.95M	193.81M	238.40M	81.60M	314.15K	1.07M
Total Debt	8.54M	31.80M	25.02M	9.78M	0.00	0.00
Total Liabilities	55.57M	53.76M	38.56M	14.47M	4.62M	4.05M
Stockholders Equity	281.55M	167.71M	272.61M	72.49M	127.42M	127.39M
Cash Flow
Free Cash Flow	-103.78M	-100.72M	-49.21M	-25.06M	-17.75M	-16.23M
Operating Cash Flow	-102.45M	-99.24M	-48.28M	-24.74M	-17.59M	-15.98M
Investing Cash Flow	-66.47M	-25.14M	-125.95M	-318.00K	-153.00K	-247.00K
Financing Cash Flow	143.18M	1.52M	265.72M	86.15M	27.97M	22.52M

enGene Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENGN, the sentiment is Negative. The current price of 7.25 is below the 20-day moving average (MA) of 9.00, below the 50-day MA of 9.33, and above the 200-day MA of 6.74, indicating a neutral trend. The MACD of -0.70 indicates Positive momentum. The RSI at 32.61 is Neutral, neither overbought nor oversold. The STOCH value of 17.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENGN.

enGene Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	61 Neutral	$1.66B	―	-0.14%	―	-52.08%	-69.35%
IMRX	56 Neutral	$310.33M	-5.17	-43.33%	―	―	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTNM	50 Neutral	$512.17M	-5.28	-30.40%	―	―	-100.71%
REPL	47 Neutral	$578.01M	-3.16	-102.69%	―	―	-15.77%
ENGN	46 Neutral	$485.67M	5.39	-5.15%	―	―	-52.86%
TVRD	46 Neutral	$34.15M	-16.53	-135.79%	―	-53.67%	86.75%